Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-10-24

Clinical Trial Update: High Dose Risankizumab for Psoriasis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating high-dose risankizumab for psoriasis has completed, with results posted on 2025-10-24.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SKYRIZI (risankizumab-rzaa)

Snippet

Sponsor: Oregon Medical Research Center | Conditions: Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2025-10-24